Indeed, in the highly aggressive streptozotocin-diabetes model ApoE−/− model of profound Type I diabetes and hyperlipidaemia, metformin acted via the methylglyoxal pathway to reduce atherosclerosis, and independently of AMPK.14 Here, PRKAB1 is linked to atherosclerosis.